drugset / Trial / NCT02429232

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

NCT02429232

Phase 4 Unknown 160 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Diabetes mellitus is a common disease with much impact on human's health and is related to osteoporosis. But the mechanism remains unclear. The foreign researches revealed thiazolidinedione (TZD) would increase the risk of osteoporosis and bone fracture, specially elderly women. However, it is still controversial in terms of the youth and men. In Taiwan,there is few related study to analyze the relationship between TZD and steoporosis. This is a multicenter randomized controlled study.

Timeline

Start
2015-10
Primary completion
2017-07
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linagliptin Small molecule 5 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral